BRKRBRUKER CORP
Laboratory Analytical Instruments
- Revenue
- $3.4B
- 2.1% YoY
- Operating margin
- 2.0%
- 74% YoY
- EBITDA
- $289M
- 34% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 0.5×
- $147M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear24% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear24% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $2.4B | $2.5B | $3.0B | $3.4B | $3.4B | 2.1% |
| Operating income | $413M | $433M | $437M | $253M | $68M | 73% |
| Net income | $281M | $299M | $429M | $114M | −$8M | 107% |
| Operating cash flow | $282M | $274M | $350M | $251M | $134M | 47% |
| Capex | $92M | $129M | $107M | $115M | $91M | 21% |
| Stock-based comp | $17M | $28M | $31M | $25M | $20M | 20% |
| Buybacks | $153M | $263M | $152M | $0 | $10M | |
| Dividends | $24M | $30M | $29M | $30M | $23M | 25% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $106K · 1
- Net
- −$106K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 88 | 68 |
| FY2024 | — | — | 110 | 70 |
| FY2023 | — | — | 137 | 75 |
| FY2022 | — | — | 127 | 84 |
| FY2021 | — | — | 155 | 126 |